Sigrid Therapeutics announces publication of scientific study showing Mesoporous Silica Particles retain their structure and function while passing through the gastrointestinal tract
Results back use of MSPs for novel diabetes and obesity treatments Stockholm, February 22, 2023: Sigrid Therapeutics today announced the publication of a scientific study featured on the cover of the peer-reviewed journal ACS Applied Materials & Interfaces demonstrating that micron-sized mesoporous silica particles (MSPs) retain their structure and function while passing through the gastrointestinal tract (GIT). The results strongly suggest that orally ingested MSPs can safely be used for several clinical applications including diabetes and obesity where they act as “molecular sieves”,